1. About : Contact Us : Minimally invasive surgical procedures for ...
TranS1 is a medical device spine company focused on minimally invasive surgical spineprocedures.
2. Rick Randall TranS1 Email CEO @trans1.com
Description: Rick Randall is TranS1 CEO. With a Lead411 subscription, TranS1 email ... js' type='text/javascript'%3E%3C/script%3E")); var pageTracker = _gat._getTracker("UA ...
3. TranS1 Inc. Announces CFO Transition | www.trans1.com
Print page Email page Download PDF « Previous Release | Next Release » TranS1 Inc. Announces CFO Transition
4. TranS1 Inc. Announces Appointment of Ken Reali as President and ...
Print page Email page Download PDF « Previous Release | Next Release » TranS1 Inc. Announces Appointment of Ken Reali as President and Chief ...
5. TranS1 Inc. (TSON.O) Company Profile | Reuters.com
Business news & Financial news from Reuters.com. ... TranS1 Inc. (TranS1), incorporated in May 2000, is a medical device company focused on designing, developing and marketing products ...
6. About : Overview : Minimally invasive surgical procedures for the ...
TranS1 is a medical device spine company focused on minimally invasive surgical procedures for the spine, designed to improve patient outcomes and surgical ease-of-use.
7. TranS1 Inc. (TSON.O) Key Developments | Reuters.com
Business news & Financial news from Reuters.com. ... TranS1 Inc. Issues Q4 2010 Revenue Guidance Below Analysts' Estimates Tuesday, 9 Nov 2010 04:01pm EST
8. Trans1 - Cafepharma Message Boards
Are any of you on the spine side seeing Trans1 cases pop up for you 5-1 fusions? I definitely see an advantage to their technique, although it is much different than traditional ...
9. TranS1 - Company Profile | LinkedIn
This LinkedIn Company Profile was created by LinkedIn and is about TranS1. This page is not endorsed by or affiliated with TranS1. For questions regarding LinkedIn Company Profiles ...
10. TranS1 Inc. Reports Operating Results for the Third Quarter of ...
- Third quarter revenues were $6.3 million - ... - Third quarter revenues were $6.3 million - - 589 TranS1 procedures performed globally in the quarter -
